Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT?

Bone Marrow Transplantation

Volumn 28, Issue 1, 2001, Pages 39-45

  Ancin I ^a   Ferra C ^a   Gallardo, D ^a   Peris, J ^a   Berlanga, J ^a   Gonzalez, J R ^a   Virgili, N ^b   Graena A ^a  

^a HOSPITAL DURAN I REYNALS   (Spain)

^b Hospital Principes de Espana   (Spain)

Author keywords

Acute graft versus host disease prophylaxis; Allogeneic bone marrow transplantation; Corticosteriods

Indexed keywords

ANTIHYPERTENSIVE AGENT; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HLA ANTIGEN; INSULIN; MELPHALAN; METHOTREXATE; PREDNISONE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DONOR; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOPROPHYLAXIS; INCIDENCE; INFECTION; MALE; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; MUSCULOSKELETAL DISEASE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SIBLING; SURVIVAL; WHOLE BODY RADIATION;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CAUSE OF DEATH; CYCLOSPORINE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; HYPERTENSION; INFECTION; MALE; METHOTREXATE; MIDDLE AGED; MUSCULOSKELETAL DISEASES; PREDNISONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THERAPEUTIC EQUIVALENCY; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034906425     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703085     Document Type: Article

References (47)

1. Treatment of 144 patients with severe aplastic anemia using immunosuppression and allogeneic marrow transplantation. A report from the International Bone Marrow Transplantation Registry
2. Treatment of moderate/severe acute graft versus host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome
3. Incidence of acute graft versus host disease with and without methotrexate prophylaxis in bone marrow transplant patients
4. Hyperacute graft versus-host disease in patients not given immunosuppression after allogeneic marrow transplant
5. Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease
6. Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy
7. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: Long-term follow-up of three controlled trials
8. Cyclosporine as prophylaxis for graft-versus-host disease: A randomized study in patients undergoing marrow transplantation for acute nonlymphocytic leukemia
9. Marrow transplantation for chronic myelocytic leukemia: A controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease
10. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia
11. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial
12. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts to severe aplastic anaemia: Long-term follow-up of a controlled trial
13. Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings
14. A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: Methotrexate/prednisone v cyclosporine A/prednisone
15. Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: A randomized double-blind study in patients undergoing allogeneic marrow transplantation
16. Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease
17. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: A prospective, randomized trial
18. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease
19. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease
20. Prevention and treatment of acute graft-versus-host disease: The old and the new
21. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?
22. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: Comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone
23. A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment
24. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention
25. Avascular necrosis of bone after allogeneic bone marrow transplantation: Clinical findings, incidence and risk factors
26. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation
27. Parenteral nutrition in patients with diabetes mellitus: Theoretical and practical considerations
28. Non parametric estimation from incomplete observations
29. Regression models and life-tables
30. Continuous infusion cyclosporine and nifedipine to day + 100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants
31. T cell depletion of HLA-identical transplants in leukemia
32. Chimerism studies using in situ hybridisation for the Y chromosome after T cell depleted bone marrow transplantation
33. Analysis of T cell repopulation after allogeneic bone marrow transplantation: Significant differences between recipients of T cell depleted and unmanipulated grafts
34. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts
35. T cell depletion in bone marrow transplantation for leukemia: Current results and future directions
36. Effect of T cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease free survival in unrelated marrow transplants for chronic myelogenous leukemia
37. T cell depletion for allogeneic bone marrow transplantation: Impact on graft-versus-host disease, engraftment and graft-versus-leukemia
38. + cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase
39. Low dose T-cell lymphocyte infusion combined with marrow T-cell depletion as prophylaxis of acute graft vs host disease for HLA identical sibling bone marrow transplantation
40. Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis
41. Phase III study comparing methotrexate and tracrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-graft disease prophylaxis after HLA-identical sibling bone marrow transplantation
42. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation
43. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors
44. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation
45. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation
46. Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia
47. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: Results of a randomized trial